Stepanović, Aleksandar (57201691091)Aleksandar (57201691091)StepanovićNikitović, Marina (6602665617)Marina (6602665617)NikitovićBogdanović, Andrija (6603686934)Andrija (6603686934)BogdanovićGrujičić, Danica (7004438060)Danica (7004438060)Grujičić2025-06-122025-06-122020https://doi.org/10.12890/2020_001785https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141861757&doi=10.12890%2f2020_001785&partnerID=40&md5=11077b67f1d8f7c206f9e0cbf9e95bcbhttps://remedy.med.bg.ac.rs/handle/123456789/4783We describe long-lasting and incompletely resolved thrombocytopenia after transient profound pancytopenia in a 62-year-old female patient with glioblastoma after short-term radiotherapy with temozolomide. Pancytopenia was present for more than 4 weeks and thrombocytopenia for more than 6 months, without platelet recovery to normal levels. Learning Points • Some patients may experience severe haematological manifestations after even short-term radiotherapy with temozolomide. • In everyday practice, clinical models precisely predicting the haematological toxicity of concomitant treatment with temozolomide and radiotherapy is necessary, especially in countries where genetic tests are not available. • Incomplete recovery of the cells of a particular bloodline over a long period may necessitate permanent discontinuation of chemotherapy or radiotherapy. © 2020 EFIM.GlioblastomaPancytopeniaTemozolomideThrombocytopenia